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AbstrACt
Objective A new prognostic model has been developed 
and externally validated, the aim of which is to assist in the 
management of the blunt chest wall trauma patient in the 
emergency department (ED). The aim of this trial is to assess 
the feasibility and acceptability of a deinitive impact trial 
investigating the clinical and cost-effectiveness of a new 
prognostic model for the management of patients with blunt 
chest wall trauma in the ED.
Design Stepped wedge feasibility trial.
setting Four EDs in England and Wales.
Participants Adult blunt chest wall trauma patients 
presenting to the ED with no concurrent, life-threatening 
injuries.
Intervention A prognostic model (the STUMBL score) to 
guide clinical decision-making.
Outcome measures Primary: participant recruitment 
rate and clinicians’ use of the STUMBL score. Secondary: 
composite outcome measure (mortality, pulmonary 
complications, delayed upgrade in care, unplanned 
representations to the ED), physical and mental 
components of quality of life, clinician feedback and health 
economic data gathering methodology for healthcare 
resource utilisation.
results Quantitative data were analysed using the 
intention-to-treat principle. 176 patients were recruited; 
recruitment targets were achieved at all sites. Clinicians used 
the model in 96% of intervention cases. All feasibility criteria 
were fully or partially met. After adjusting for predeined 
covariates, there were no statistically signiicant differences 
between the control and intervention periods. Qualitative 
analysis highlighted that STUMBL was well-received and 
clinicians would support a deinitive trial. Collecting data 
on intervention costs, health-related quality of life and 
healthcare resource use was feasible.
Discussion We have demonstrated that a fully powered 
randomised clinical trial of the STUMBL score is feasible 
and desirable to clinicians. Minor methodological 
modiications will be made for the full trial.
trial registration number ISRCTN95571506; Post-
results.
IntrODuCtIOn
Blunt chest wall trauma accounts for over 
15% of all trauma admissions to emergency 
departments (EDs) worldwide, with reported 
mortality ranging between 4% and 60%.1–3 
Difficulties in the management of blunt chest 
wall trauma patients in the ED are becoming 
increasingly well recognised in the litera-
ture.4 5 The patient commonly presents to 
the ED with no respiratory difficulties, but 
can develop complications up to approxi-
mately 72 hours after initial presentation.1–4 
Clinical symptoms are not considered by 
most clinicians to be an accurate predictor of 
outcome following non-life-threatening blunt 
chest wall trauma.1–7 Decisions regarding 
the appropriate level of care required by 
strengths and limitations of this study
 Ź The main strength of this feasibility trial is that it has 
tested all of the methodological components of the 
future deinitive trial, including the trial infrastruc-
ture, randomisation process, data management 
system, both qualitative and quantitative analy-
sis, follow-up procedures and a health economic 
analysis.
 Ź The health economic analysis undertaken will en-
sure accurate future funding applications for the full 
deinitive trial.
 Ź The qualitative analysis has informed the researcher 
teams’ understanding of the use of the risk score by 
clinicians in daily clinical practice.
 Ź The cluster randomised trial design that needed to 
be tested in this feasibility trial was limited by the 
small number of clusters (emergency departments 
participating). In the future deinitive trial, more clus-
ters will be possible, due to the greater number of 
participating sites.
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the patient following discharge from the ED are there-
fore difficult and are further compounded by the lack of 
current national guidelines. Improvements in identifica-
tion of high-risk patients on initial assessment in the ED 
could lead to a reduction in these poor outcomes.8 9 
A new prognostic model (STUMBL Score) to assist the 
management of blunt chest wall trauma patients in the 
ED has been developed and externally validated in a large 
multicentre study.1 5–7 Guidelines recommend that prog-
nostic models should not be used in clinical practice until 
an impact trial has been completed, in which the clinical 
application of the model has been tested.10 11 The aim of 
this trial was to establish the feasibility and acceptability 
of a future definitive trial, which will determine whether 
the prognostic model can be used safely and effectively in 
clinical practice in the UK.
MethODs
trial design and randomisation
This was a multicentre, prospective, cluster randomised 
(stepped wedge) trial12 with a qualitative component. 
The unit of randomisation was the ED, rather than the 
patient, since the intervention was used by ED clinicians 
with the aim of studying effects on patient outcomes.13 All 
EDs began as controls testing conventional management 
without the model for a period of 1 month. Every month, 
one hospital was randomly assigned to the intervention 
period (using the prognostic model), until all hospitals 
were intervention sites. Online supplementary file 1 
outlines the trial procedure, and the protocol describes 
the trial in full.14
Population
Patients presenting to the ED with isolated blunt chest 
wall trauma were included in the trial if they were aged 
18 years or over and capable of giving consent to partici-
pation. Exclusion criteria were under the age of 18 years, 
lacked capacity to give informed consent, presented with 
immediately life-threatening injuries or any concurrent 
injury that would determine the patient’s management.
Patient and public involvement
Two ex-trauma patients were members of the STUMBL 
Trial Development Group that developed the protocol 
and designed the study. They continued to sit on the 
Trial Management Group, attending all research meet-
ings and contributing to the overall running of the trial. 
A further two ex-trauma patients sat on the Trial Steering 
Committee (TSC). Trial participants were instructed to 
contact the research team if they were interested in the 
trial results.
setting and recruitment
This feasibility trial ran in four EDs in the UK: Royal 
Gwent Hospital, Newport; Musgrove Park Hospital, 
Taunton (both non-major trauma centres); Salford Royal 
Hospital and Manchester Royal Infirmary (both major 
trauma centres). ED clinicians and research nurses were 
responsible for screening, recruiting and consenting 
eligible patients to the trial.
sample size
The trial had a 5-month recruitment period, and each 
hospital aimed to recruit 30–80 patients. This was the 
minimum number considered necessary to test data 
collection processes based on existing recommendations 
for meaningful estimates of parameters of interest.15 This 
recruitment period also allowed for loss to follow-up, low 
response rates with follow-up surveys and difficulties with 
recruiting at weekends if research nurses only worked 
Monday to Friday.
Intervention
The intervention was a prognostic model to guide clini-
cians' decision-making. The model was used during 
initial patient assessment and provided a suggestion of 
the appropriate management (whether the patient could 
be safely discharged home or needed admission to either 
a ward or a critical care). Participants were asked to 
complete one survey (SF-12v1)16 on initial presentation 
and two more surveys at 6 weeks (SF-12v1 and a Client 
Services Receipt Inventory (CSRI)). Online supplemen-
tary file 2 illustrates the patients’ journey.
Outcome measures
Primary outcome measures
1. Patient recruitment rate.
2. Clinicians’ use of the model in the intervention 
period.
Secondary outcome measures
Patient outcomes: (1) composite outcome measure: 
which includes in-hospital mortality, pulmonary compli-
cations (chest infection, pneumonia, pneumothorax, 
haemothorax, pleural effusion or empyema) diagnosed 
during hospital admission, delayed upgrade in care 
(defined as a deterioration in a patient’s condition on the 
ward, requiring admission to critical care) and unplanned 
representations to the ED, (2) overall mean quality of life 
(as reported by SF-12v1 survey).
Organisational outcomes: (1) clinician recruitment 
rate, (2) participant questionnaire response rate and (3) 
clinicians training attendance rate.
Qualitative outcomes: (1) clinician feedback regarding 
training quality and use of the prognostic model in clin-
ical practice, (2) clinician and research nurse feedback 
regarding trial methods.
Health economic outcomes: (1) trainer/trainee hourly 
rates/training time/travelling time, (2) equipment 
costs and (3) resource usage by patients during the trial 
period.
Criteria for establishing feasibility
In order to evaluate the feasibility of a full definitive trial, 
the TSC assessed the findings against predetermined 
success criteria (box 1) using a traffic light system.17
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Traffic light assessment: Green means the target was 
achieved, amber means the target was not achieved but 
progression is possible with some minor protocol modi-
fications and red means progression to a full trial is not 
possible.
Data collection and management
Research Electronic Data Capture18 was used for data 
capture, management and completion of the electronic 
case report forms.
Data analysis
Quantitative analyses were performed on Stata V.15.1 
SE using the intention-to-treat principle and were not 
powered to detect clinically important effects. Results 
are presented as numbers (percentages), means (SD) 
and medians (interquartile ranges) where non-normally 
distributed. Baseline characteristics between groups were 
completed using the Wilcoxon rank-sum test and Fisher’s 
exact test. The risk score was also calculated retrospec-
tively for control cases for baseline comparisons purposes 
only.
A binary composite outcome measure was calculated, 
indicating if the participant had experienced at least one 
of the contributing factors (mortality, unplanned repre-
sentation to the ED, delayed upgrade in care or onset of 
pulmonary complications). Intervention/control groups 
were compared using logistic regression analysis (using 
exact logistic regression where there were zero-count 
cells). Covariates included age at the time of presentation, 
the number of clinically suspected rib fractures, prein-
jury use of anticoagulants, the presence of pre-existing 
chronic lung disease and oxygen saturation on initial 
assessment in the ED. Analysis of individual components 
of the composite outcome measure was completed using 
the same method.
Sensitivity analyses were undertaken following clinical 
review of the data. The following factors were considered: 
the type of logistic regression analysis used, inclusion of 
additional covariates, representations leading to imme-
diate discharge and unrelated representations/deaths. 
Each was analysed individually, on the composite outcome 
measure, with all covariates included.
 A purposive sample of the clinicians based on seniority, 
location and trial participation were invited to take part in 
a short interview in which they were asked to discuss the 
model in relation to their clinical practice. Two research 
nurses (where available, the Royal Gwent Hospital only 
had one research nurse) from each site were asked to 
attend a focus group in which the trial’s methodology was 
discussed. One site was unable to attend. Focus group and 
interviews were audio-recorded and transcribed verbatim 
by a professional transcription service. The qualitative 
researcher (CO’N) monitored this process; transcripts 
were checked for accuracy against the original recording 
and were anonymised in accordance with best practice 
standards. The cleaned and anonymised transcripts were 
uploaded into NVIVO V.11.19
Thematic analysis was used to analyse the transcripts 
using a code book, which developed initially from the 
background literature and feedback on the training 
as well as issues that emerged through the process of 
constant comparison, which underpins qualitative data 
analysis. Due to the small numbers of transcripts, the 
coded transcripts were checked by a second qualitative 
researcher, using the coder comparison query tool.
Health economic analysis focused on establishing the 
most appropriate framework for a future health economic 
analysis. The feasibility of collecting data on quality of life 
and resource use was assessed, along with a provisional 
assessment of cost categories associated with the inter-
vention (eg, staff training time). To capture resource use 
by patients from an NHS/PSS (National Health Service/
Personal Social Service) perspective, an adapted resource 
usage questionnaire was used. Data were assessed to 
examine the completeness of data captured, such as 
response rate and missing items.
results
All sites were able to recruit over the 5-month period, 
and there were no difficulties implementing the stepped 
wedge design (online supplementary file 1). There were 
no obvious differences between numbers recruited at 
each site when considering major trauma centre status, 
with the Royal Gwent Hospital recruiting 31 patients, 
Musgrove Park Hospital recruiting 47 patients (plus 
one withdrawal of consent), Salford Royal Hospital 
recruiting 38 patients and Manchester Royal Infirmary 
recruiting 60 patients (figure 1). There was some incon-
sistency around screening/consenting between sites. For 
example, research nurse availability affected the recruit-
ment and consent process in smaller sites. Another incon-
sistency occurred as one site did not keep a screening log 
throughout the trial.
box 1 trial feasibility criteria
Primary outcomes
1. 80% or more of eligible patients consent to data collection and 
follow-up.
2. 90% or more use of the model by clinicians during intervention 
period.
secondary outcomes
3. 95% or more of clinicians working within the participating emergen-
cy department agree to take part in the trial.
4. Follow-up data for patient secondary outcomes can be collected for 
80% or more of patients.
5. All clinicians involved in the trial receive formal training in the use 
of the model.
6. Patient secondary outcome measures reported in the intervention 
period are equal to, or better than, those reported during the con-
ventional management period.
7. Mean quality of life reported in intervention arm is not less than 80% 
of that reported in control arm.
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Feasibility criteria
All feasibility criteria were green or amber (table 1). The 
primary outcomes were both green. It proved impractical 
to obtain precise figures for the number of clinicians 
working in EDs over the trial period, but the information 
available suggests that no one dissented from using the 
tool and all were appropriately trained. There were initial 
difficulties in obtaining follow-up questionnaire data; 
however, response rates improved once telephone and 
email follow-ups were introduced, justifying the amber 
status. Clinical follow-up data were only from hospital 
records (ie, participants who were admitted or subse-
quently represented to hospital).
baseline characteristics
The intervention group was significantly older, with more 
severe injuries and more likely to sustain a low velocity 
fall, when compared with the control group. There were 
Figure 1 STUMBL CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials; CSRI, Client Services Receipt 
Inventory .
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a significantly higher number of road traffic accidents 
in the control group (table 2). To understand the differ-
ences between groups, we retrospectively calculated the 
risk score for participants in the control group using 
routinely collected data. We found that the interven-
tion group scored significantly higher on the prognostic 
model than the control group.
Clinical outcomes
There was a complication rate of 8%, when considering 
the composite outcome measure (table 3). The ORs for 
mortality and delayed upgrade in care were calculated 
using exact logistic regression with no covariates due to 
0-count cells.
Results of the quality of life analysis (SF-12v1) found no 
statistically significant difference between the interven-
tion and control groups, in either the physical or mental 
components (table 4).
sensitivity analysis—composite outcome measure only
The type of regression analysis undertaken had the 
largest effect on the results. Due to the low number of 
events seen, we considered the impact of using an exact 
logistic regression (using the Stata exlogistic command) 
and a Penalised Maximum Likelihood Estimation (the 
‘Firth method’, using the Stata firthlogit command). 
Exact logistic regression produced results consistent with 
our initial calculation; the Firth method produced results 
that were more favourable to the intervention. Further 
analysis that considered other covariates made little 
difference to the overall findings, nor did whether the 
prognostic model’s management guidance was followed, 
accounting for the unrelated deaths/representations, or 
our assumption that all pulmonary complications diag-
nosed on the day of randomisation were present at admis-
sion. Excluding representations leading to a discharge 
had a large impact on the size of the 95% CI, but this may 
be due to very low number of events remaining for anal-
ysis (online supplementary file 3).
Missing data
Some data did not appear to be missing entirely at 
random, with one site missing considerably more data 
than the others. Exploration suggested that this was due 
to lower research nurse levels and unforeseeable circum-
stances. There was difficulty in obtaining completed CSRI 
forms compared with SF-12s. Some CSRIs were completed 
by research nurses using available NHS records and 
contacting General Practitioner (GPs), particularly in 
one of the early intervention sites, leading to a higher 
proportion completed than would otherwise be the case.
serious adverse events
Two deaths were reported. One was unrelated to the 
chest injury, the other patient was placed on a palliative 
care pathway following admission to hospital.
Qualitative results
Four research nurses attended the focus group and nine 
clinician interviews were completed. Thirty-six training 
Table 1 Feasibility outcomes
Feasibility criteria Result
Feasibility 
assessment
Primary outcomes
80% or more of eligible patients consent to data collection and follow-
up (patients approached to participate in trial: n=186)
176/186 (94.6%) Green
90% use of the model during intervention period (n=76 in intervention 
period)
Model used in 73 cases 
(96.1%)
Green
Secondary outcomes
95% or more of clinicians working within the participating ED agree to 
take part in the trial
100% Green
 Follow-up data for patient secondary outcomes can be collected for 
80% or more of patients (n=176)
Clinical data: 176 (100%)
SF-12: 128 (72.7%)
CSRI data available: 137 
(78.8%)
Green
Amber
Amber
All clinicians involved in the trial receive formal training in the use of 
the model
100% Green
Patient secondary outcome measures reported in the intervention 
period are equal to, or better than, those reported during the 
conventional management period
See table 3 below Amber
Mean quality of life reported in intervention arm is not less than 80% 
of that reported in control arm
See table 4 below Green
Number of cases (percentages). Feasibility criteria trafic light system: green, feasibility criteria achieved; amber, feasibility criteria not 
achieved but progression is possible with some minor protocol modiications.
 CSRI, Client Services Receipt Inventory; ED, emergency department.
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Table 2 Baseline subject characteristics
Characteristic Categories Control period Intervention period Overall
Gender n=100 n=76 n=176
Male 65 (65.0%) 53 (69.7%) 118 (67.1%)
Female 35 (35.0%) 23 (30.3%) 58 (32.9%)
Age n=100 n=76 n=176
Years 48.9 (17.8) 55.0 (17.8) 51.5 (18.0)*
Number of clinically suspected 
rib fractures
Number n=100
0 (0, 1)
n=76
1 (0, 2)
n=176
0.5 (0, 1)*
Preinjury anticoagulant use n=99 n=73 n=172
Yes 3 (3.0%) 6 (8.2%) 9 (5.2%)
No 96 (97.0%) 67 (91.8%) 163 (94.8%)
Pre-existing lung disease n=100 n=76 n=176
Yes 10 (10.0%) 7 (9.2%) 17 (9.7%)
No 90 (90.0%) 69 (90.8%) 159 (90.3%)
Oxygen saturation at initial 
assessment
n=92 n=70 n=162
95%–100% 80 (87.0%) 67 (95.7%) 147 (90.7%)
94%–90% 11 (12.0%) 3 (4.3%) 14 (8.6%)
85%–89% 1 (1.09%) 0 (0.0%) 1 (0.6%)
80%–84% 0 (0.0%) 0 (0.0%) 0 (0.0%)
75%–79% 0 (0.0%) 0 (0.0%) 0 (0.0%)
70%–74% 0 (0.0%) 0 (0.0%) 0 (0.0%)
Prognostic model Total score n=91
5 (3–9)
n=67
9 (5–13)
n=158
7 (4–11)*
Mechanism of injury n=100 n=76 n=176
Low velocity fall 27 (27.0%) 44 (57.9%) 71 (40.3%)† 
High velocity fall 14 (14.0%) 9 (11.8%) 23 (13.1%)
RTA 20 (20.0%) 5 (6.6%) 25 (14.2%)†
Contact sport 4 (4.0%) 3 (3.9%) 7 (4.0%)
Alleged assault 7 (7.0%) 5 (6.6%) 12 (6.8%)
Other 28 (28.0%) 10 (13.2%) 38 (21.6%)
Quality of life score (measured 
by SF-12)
Physical Component Score n=100
41.0 (30.7–49.9)
n=76
43.6 (31.8–52.1)
n=176
41.5 (31.5–50.2)
Mental Component Score n=100
54.0 (44.5–59.4)
n=76
55.8 (50.2–58.0)
n=176
55.3 (46.4–59.0)
Presenting with pulmonary 
complications
n=100 n=76 n=176
Yes 1 (1.0%) 5 (6.6%) 6 (3.4%)
No 99 (99.0%) 71 (93.4%) 170 (96.6%)
Preinjury antiplatelet use n=99 n=73 n=172
Yes 5 (5.1%) 6 (8.2%) 11 (6.4%)
No 94 (94.9%) 67 (91.8%) 161 (93.6%)
Frailty score n=92 n=60 n=152
Very it 50 (54.3.%) 32 (53.3%) 82 (53.9%)
Well 24 (26.1%) 19 (31.7%) 43 (28.3%)
Managing well 8 (8.70) 5 (8.3%) 13 (8.6%)
Vulnerable 9 (9.8%) 1 (1.7%) 10 (6.6%)
Moderately frail 1 (1.1%) 2 (3.3%) 3 (2.0%)
Severely frail 0 (0.0%) 1 (1.7%) 1 (0.7%)
Continued
7Battle C, et al. BMJ Open 2019;9:e029187. doi:10.1136/bmjopen-2019-029187
Open access
feedback questionnaires were completed. Following 
coding, three main themes covering issues of process, 
impact and mainstreaming were identified.
Trial processes refer to informants’ perspectives on 
the running of the trial from planning and design issues 
through to data collection, publicity and training. Staff 
were positive about the trial, they liked the stepped wedge 
design and data collection was largely unproblematic. 
The use of social media was commended and staff were 
keen for this to be retained. Using Twitter to drive patient 
recruitment was highlighted by everyone as a great moti-
vator and a way to encourage team involvement and to 
drive recruitment.
The consent model used in this trial, and the alterna-
tive of presumed consent, was not considered contentious 
by the teams. The training was well received and could 
be offered in different formats. Data collection tools and 
improvements made to them during the trial were consid-
ered appropriate. Some improvements such as telephone 
follow-ups worked well. Otherwise, there were no other 
suggested changes regarding trial processes. It was clear 
that staff appreciated the value of the STUMBL Score 
and would support a definitive trial to ensure its wider 
implementation.
health economic evaluation
There were no significant differences in quality of life 
between control and intervention groups at either baseline 
or follow-up. However, analysis only included complete 
cases (n=126 of 176), with no imputation undertaken, 
and should be viewed with caution. The mean training 
time was 31 min (SD: 24 min), and it usually took place at 
a trainee’s place of work. As the pay grades for clinicians 
varied, training costs varied substantially between £6.45 
and £108 per session (mean = £31.82, SD = £20.6). When 
training could be carried out in a trainee’s place of work, 
the cost per person was minimised.
The CSRI and SF-12 captured the data required for a 
full economic evaluation in the main trial. Measures can 
be taken to adapt the instruments to capture key data that 
are likely to have a greater impact on costs.
DIsCussIOn
This is the first trial to test the feasibility of conducting a 
cluster-randomised controlled trial into the effectiveness 
of a prognostic model for the management of blunt chest 
wall trauma patients presenting to the ED. All feasibility 
criteria were met, suggesting that progression to a full 
impact trial is possible.
Characteristic Categories Control period Intervention period Overall
Presented at major trauma 
centre
n=100 n=76 n=176
Yes 66 (66.0%) 32 (42.1%) 98 (55.7%)†
No 34 (34.0%) 44 (57.9%) 78 (44.3%)
Time site in trial stage at 
presentation
Time in days 36.5 (18–57) 23.5 (11–46) 29.5 (15–54)*
Mean (SD); median (IQR); n, non-missing sample size; number (%).
*Signiicant p<0.05 using Wilcoxon rank sum test.
†Signiicant p<0.05 using Fisher’s exact test.
RTA, road trafic accident.
Table 2 Continued 
Table 3 Secondary outcome measure (composite measure)
Criteria Total n=176
Control period 
n=100
Intervention period 
n=76 Adjusted OR (95%)
Composite outcome measure 14 (8.0%) 4 (4.0%) 10 (13.2%) 3.89 (1.01, 14.95)
Secondary outcome measures
  Mortality 2 (1.1%) 0 (0.0%) 2 (2.6%) 3.24 (0.25, +ininity)
  Unplanned presentations to ED 10 (5.7%) 3 (3.0%) 7 (9.2%) 4.89 (0.97, 24.80)
  Delayed upgrade in care 1 (0.6%) 0 (0.0%) 1 (1.3%) 1.32 (0.03, +ininity)
  Onset of pulmonary complications 3 (1.7%) 1 (1.0%) 2 (2.6%) 2.41 (0.09, 66.78)
Number (%); adjusted ORs calculated using logistic command. The composite outcome measure was a binary variable indicating if the 
participant had at least one of the contributing secondary outcome measures (mortality, unplanned representation to the ED, delayed upgrade 
in care or onset of pulmonary complications).
ED, emergency department.
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This trial has highlighted some minor modifications 
that need to be made to the methods prior to moving 
forward to the full trial. Research nurse availability varied 
substantially between sites. In one of the smaller (trauma 
unit) sites, difficulties in patient recruitment were noted 
due to the fact that there was only one research nurse 
working on the trial, so out-of-hours recruitment was 
not possible. This suggests that capacity is something to 
consider carefully when recruiting sites for any future 
definitive trial. Reliance on research nurses to recruit 
participants, rather clinicians recruiting as part of patient 
management, will need consideration when planning the 
future trial. A retrospective consent model was discussed 
in some clinician interviews, which may need consider-
ation as one strategy to improve recruitment numbers.
Participant outcomes were compared to ensure that 
there were no large differences between groups and that 
we remain in equipoise regarding use of the model in EDs. 
Although analysis of the composite outcome measure 
suggests a difference between groups, this may be because 
the two major trauma centres were the last sites to tran-
sition to the intervention (and therefore had longer in 
the control phases) and collectively, they recruited most 
patients to the trial. The intervention group was signifi-
cantly older, more severely injured and scored higher 
on the prognostic model than the control group (using 
retrospective scores for the control group). A larger 
number of sites will be used in the future trial, which 
should reduce baseline variation. Overall, the trial popu-
lation was younger than previous research1 6 by the group 
which may be due to the inclusion of a higher proportion 
of major trauma centres. Due to a low number of adverse 
events compared with previous research, the regression 
analysis produced wide CIs. This trial is not powered to 
detect differences in outcomes, and therefore any differ-
ences between groups should be considered with caution.
The complication rate was lower than that reported in 
our development and validation work.1 6 This could be 
explained by the proportion of major trauma centres 
included in this trial, when compared with the previous 
work, although this would need further investigation. 
This information will prove useful when calculating the 
sample for a full trial.
There was difficulty in obtaining completed CSRI 
surveys. As a result, some CSRIs were completed by 
research nurses using available NHS records and 
contacting GPs. The most costly data gathered from the 
CSRI questionnaire would normally be inpatient stays 
and outpatient visits, especially when there are multiple 
stays/visits following the initial visit to the ED. Unfortu-
nately, an oversight of the timing of the CSRI meant ques-
tions only asked about the 6 weeks following discharge, 
resulting in a failure to capture costs involved in the initial 
ED treatment. This is a key cost driver, and in a full trial, 
the CSRI questions would be amended to capture recall 
since arrival at ED.
In conclusion, this work has demonstrated that progres-
sion to the full definitive impact trial is feasible, with some 
minor modifications.
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Table 4 Health-related quality of life
Control group Intervention group
Physical Component Score at baseline 41.0 (30.7 to 49.9); n=100 43.6 (31.8 to 52.1); n=76
Physical Component Score at follow-up 50.1 (38.5 to 54.5); n=75 43.8 (34.3 to 52.1); n=51
Change in Physical Component Score 4.45 (−1.1 to 15.7); n=75 0 (−7.8 to 12.1); n=51
Mental Component Score at baseline 54.0 (44.5 to 59.4); n=100 55.8 (50.2 to 58.0); n=76
Mental Component Score at follow-up 53.1 (45.4 to 58.7); n=75 55.2 (42.2 to 58.7); n=51
Change in Mental Component Score −0.1 (−8.1 to 4); n=75 −2.4 (−10.6 to 2.3); n=51
Data are presented as median (IQR). Only complete forms were included in this analysis; no imputation was undertaken.
9Battle C, et al. BMJ Open 2019;9:e029187. doi:10.1136/bmjopen-2019-029187
Open access
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
reFerenCes
 1. Battle CE, James K, Hutchings H, et al. Risk factors for the 
development of complications in blunt chest wall trauma: a 
retrospective study. Injury 2013;44:1171–6.
 2. Brasel KJ, Guse CE, Layde P, et al. Rib fractures: relationship with 
pneumonia and mortality. Crit Care Med 2006;34:1642–6.
 3. Bergeron E, Lavoie A, Clas D, et al. Elderly trauma patients with 
rib fractures are at greater risk of death and pneumonia. J Trauma 
2003;54:478–85.
 4. Unsworth A, Curtis K, Asha SE. Treatments for blunt chest trauma 
and their impact on patient outcomes and health service delivery. 
Scand J Trauma Resusc Emerg Med 2015;23:17.
 5. Battle CE, Hutchings H, Evans PA. Risk factors that predict mortality 
in patients with blunt chest wall trauma: a systematic review and 
meta-analysis. Injury 2012;43:8–17.
 6. Battle C, Hutchings H, Lovett S, et al. Predicting outcomes after 
blunt chest wall trauma: development and external validation of a 
new prognostic model. Crit Care 2014;18:R98.
 7. Battle CE, Hutchings H, Evans PA. Expert opinion of the risk factors 
for morbidity and mortality in blunt chest wall trauma: results of a 
national postal questionnaire survey of Emergency Departments in 
the United Kingdom. Injury 2013;44:56–9.
 8. Ahmad MA, Delli Sante E, Giannoudis PV. Assessment of severity of 
chest trauma: is there an ideal scoring system? Injury 2010;41:981–3.
 9. Blecher GE, Mitra B, Cameron PA, et al. Failed Emergency 
Department disposition to the ward of patients with thoracic injury. 
Injury 2008;39:586–91.
 10. Moons KG, Altman DG, Vergouwe Y, et al. Prognosis and prognostic 
research: application and impact of prognostic models in clinical 
practice. BMJ 2009;338:b606–90.
 11. Moons KGM, Royston P, Vergouwe Y, et al. Research methods and 
reporting Prognosis and prognostic research: what, why and how? 
BMJ 2009;338:1317–20.
 12. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic 
review. BMC Med Res Methodol 2006;6:54.
 13. Medical Research Council. Developing and evaluating complex 
interventions: new guidance. www. mrc. ac. uk/ comp lexi nter vent ions 
guidance
 14. Battle C, Abbott Z, Hutchings HA, et al. Protocol for a multicentre 
randomised feasibility STUdy evaluating the impact of a prognostic 
model for Management of BLunt chest wall trauma patients: 
STUMBL trial. BMJ Open 2017;7:e015972.
 15. Lancaster GA, Dodd S, Williamson PR. Design and analysis of 
pilot studies: recommendations for good practice. J Eval Clin Pract 
2004;10:307–12.
 16. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: 
construction of scales and preliminary tests of reliability and validity. 
Med Care 1996;34:220–33.
 17. Charlesworth G, Burnell K, Hoe J, et al. Acceptance checklist for 
clinical effectiveness pilot trials: a systematic approach. BMC Med 
Res Methodol 2013;13:78.
 18. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture 
(REDCap)--a metadata-driven methodology and worklow process 
for providing translational research informatics support. J Biomed 
Inform 2009;42:377–81.
 19. QSR International: NVIVO. http://www. qsrinternational. com/ what- is- 
nvivo
